Glenmark announces Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated October 23, 2015 titled "Glenmark announces Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe". Q2 results on Oct 29, 2015
Glenmark Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 29, 2015, to consider and approve the Company's Unaudited Financial Statements for the Second Quarter/Half Year ended September 30, 2015 (Q2).Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window closed for Directors and other designated employees of the Company... Updates of Outcome of AGM
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of the Minutes of 37th Annual General Meeting (AGM) of the Company held on September 22, 2015. Updates
Glenmark Pharmaceuticals Ltd has informed BSE that as per the Honourable Court's Order on October 07, 2015, Glenmark has been restrained by a decree of permanent injunction from making, using, selling, distributing, advertising, exporting, offering for sale or dealing in Sitagliptin Phosphate Monohydrate or any other salt of Sitagliptin in any form, alone or in combination with one or more other drugs....
Delhi high court restrains Glenmark from selling anti-diabetes drug
The court bars Glenmark from selling, distributing, marketing or exporting its anti-diabetes drugs Zita and Zita-Met Disclosure of Voting results of AGM (Clause 35A)
Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results at the 37th Annual General Meeting (AGM) of the Company held on September 22, 2015, under Clause 35A. Glenmark to focus on organic growth, not looking at M&A; deals: Glenn Saldanha
Glenmark Pharmaceuticals will focus on organic growth and developing a pipeline of innovative products Glenmark's Bi-Specific Antibody - GBR 1302 to enter Phase I trials
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 15, 2015 titled "Glenmark's Bi-Specific Antibody - GBR 1302 to enter Phase I trials". Glenmark Pharmaceuticals receives ANDA approval for Voriconazole Tablets, 50 mg and 200 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 04, 2015 titled "Glenmark Pharmaceuticals receives ANDA approval for Voriconazole Tablets, 50 mg and 200 mg". Glenmarks novel monoclonal antibody GBR 830 to enter phase II clinical studies
GBR 830 targets activated T cells, which drives the pathology in most autoimmune diseases including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease Glenmark Pharmaceuticals GBR 830, a novel monoclonal antibody has completed clinical phase I dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation []